Log In
BCIQ
Print this Print this
 

MGN1601

  Manage Alerts
Collapse Summary General Information
Company Mologen AG
DescriptionTumor vaccine consisting of allogeneic tumor cells genetically modified to express IL-7, GM-CSF, CD80 (B7-1) and CD40 ligand (CD40LG; CD40L; CD154) in combination with a DNA immunomodulator
Molecular Target Interleukin-7 (IL-7)
Mechanism of ActionGene therapy; Vaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationRenal cancer
Indication DetailsTreat advanced renal cell carcinoma (RCC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today